Argenica Therapeutics Ltd (AGN.AX)
Argenica Therapeutics Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Nedlands, WA, AU. The stock last traded at $0.18, up 0.00% on the session, giving a market capitalisation of $23.1M. Its beta of 0.76 implies it has historically moved less than the broad market.
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Argenica Therapeutics Ltd is most often compared with the following Healthcare names: